Cargando…
Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One
Antiphospholipid antibodies (aPL) are mandatory for the diagnosis but are also a risk factor for the antiphospholipid syndrome (APS) clinical manifestations. Lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta2 glycoprotein I (β(2)GPI) assays are the formal laboratory classification/diagn...
Autores principales: | Meroni, Pier Luigi, Borghi, Maria Orietta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490700/ https://www.ncbi.nlm.nih.gov/pubmed/34621272 http://dx.doi.org/10.3389/fimmu.2021.726820 |
Ejemplares similares
-
Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications
por: Tedesco, Francesco, et al.
Publicado: (2018) -
Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added
por: Liu, Xiangjun, et al.
Publicado: (2022) -
Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
por: Li, Siting, et al.
Publicado: (2023) -
Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome
por: Lonati, Paola Adele, et al.
Publicado: (2019) -
Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome
por: Meroni, Pier Luigi, et al.
Publicado: (2019)